F V Aguirre - JoVE Visualize

Showing results (41-50 of 69) with videos related to

Pageof 7

Sort By:

Circulation|July 1, 1994

Impact of age on clinical outcome and postlytic management strategies in patients treated with intravenous thrombolytic therapy. Results from the TIMI II Study. TIMI II InvestigatorsF V Aguirre, R P McMahon, H Mueller, et al.

Journal of the American College of Cardiology|January 13, 1998

Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic ComplicationsM M Khan, S G Ellis, F V Aguirre, et al.

Catheterization and Cardiovascular Diagnosis|April 1, 1993

Superior accuracy of anatomic positioning with echocardiographic- over fluoroscopic-guided endomyocardial biopsyC A Bell, M J Kern, F V Aguirre, et al.

Journal of the American College of Cardiology|August 26, 1998

Influence of insurance type on the use of procedures, medications and hospital outcome in patients with unstable angina: results from the GUARANTEE Registry. Global Unstable Angina Registry and Treatment EvaluationN R Every, C P Cannon, C Granger, et al.

Journal of the American College of Cardiology|August 1, 1993

Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot StudyN S Kleiman, E M Ohman, R M Califf, et al.

Journal of the American College of Cardiology|July 1, 1997

Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic ComplicationsA M Lincoff, R M Califf, K M Anderson, et al.

Circulation|June 15, 1995

Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC InvestigatorsF V Aguirre, E J Topol, J J Ferguson, et al.

The American Journal of Cardiology|March 23, 1995

Clinical and operative characteristics of patients randomized to coronary artery bypass surgery in the Bypass Angioplasty Revascularization Investigation (BARI)H V Schaff, A D Rosen, R J Shemin, et al.

Circulation|October 1, 1996

Determination of angiographic (TIMI grade) blood flow by intracoronary Doppler flow velocity during acute myocardial infarctionM J Kern, J A Moore, F V Aguirre, et al.

Journal of the American College of Cardiology|January 1, 1995

Clinical outcome of deferring angioplasty in patients with normal translesional pressure-flow velocity measurementsM J Kern, T J Donohue, F V Aguirre, et al.

Pageof 7

Showing results (41-50 of 69) with videos related to

Sort By:

Pageof 7

Circulation|July 1, 1994

Impact of age on clinical outcome and postlytic management strategies in patients treated with intravenous thrombolytic therapy. Results from the TIMI II Study. TIMI II InvestigatorsF V Aguirre, R P McMahon, H Mueller, et al.

Journal of the American College of Cardiology|January 13, 1998

Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic ComplicationsM M Khan, S G Ellis, F V Aguirre, et al.

Catheterization and Cardiovascular Diagnosis|April 1, 1993

Superior accuracy of anatomic positioning with echocardiographic- over fluoroscopic-guided endomyocardial biopsyC A Bell, M J Kern, F V Aguirre, et al.

Journal of the American College of Cardiology|August 26, 1998

Influence of insurance type on the use of procedures, medications and hospital outcome in patients with unstable angina: results from the GUARANTEE Registry. Global Unstable Angina Registry and Treatment EvaluationN R Every, C P Cannon, C Granger, et al.

Journal of the American College of Cardiology|August 1, 1993

Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot StudyN S Kleiman, E M Ohman, R M Califf, et al.

Journal of the American College of Cardiology|July 1, 1997

Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic ComplicationsA M Lincoff, R M Califf, K M Anderson, et al.

Circulation|June 15, 1995

Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC InvestigatorsF V Aguirre, E J Topol, J J Ferguson, et al.

The American Journal of Cardiology|March 23, 1995

Clinical and operative characteristics of patients randomized to coronary artery bypass surgery in the Bypass Angioplasty Revascularization Investigation (BARI)H V Schaff, A D Rosen, R J Shemin, et al.

Circulation|October 1, 1996

Determination of angiographic (TIMI grade) blood flow by intracoronary Doppler flow velocity during acute myocardial infarctionM J Kern, J A Moore, F V Aguirre, et al.

Journal of the American College of Cardiology|January 1, 1995

Clinical outcome of deferring angioplasty in patients with normal translesional pressure-flow velocity measurementsM J Kern, T J Donohue, F V Aguirre, et al.

Pageof 7